Target-specific delivery of peptide-based probes for PET imaging

Advanced Drug Delivery Reviews

Volumn 62, Issue 11, 2010, Pages 1005-1022

  Chen, Kai ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Peptide based probes; PET imaging; Target specific delivery

Indexed keywords

BIO-CONJUGATION; BIOLOGICAL PROCESS; CLINICAL MANAGEMENT; CLINICAL STUDY; CURRENT STATUS; DIAGNOSTIC IMAGING; IN-VIVO; LABELING METHODS; LOW MOLECULAR WEIGHT; MOLECULAR LEVELS; MOLECULAR TARGETS; NON-INVASIVE; PEPTIDE RECEPTOR; PET IMAGING; PET PROBE; RADIOLABELING; SUB-CELLULAR;

ANTIBODIES; MOLECULAR BIOLOGY; MOLECULAR PHYSICS; PEPTIDES; POSITRON EMISSION TOMOGRAPHY; POSITRONS; PROBES; RADIOISOTOPES;

MEDICAL IMAGING;

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; CARBON 11; COPPER 64; FLUORINE 18; FLUOROBENZALDEHYDE BUTYLMALEIMIDE OXIME F 18; FLUOROBENZALDEHYDE F 18; FLUOROBENZAMIDO ETHYLMALEIMIDE F 18; FLUOROBENZOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; FLUOROPROPRIONIC ACID F 18; FLUOROPYRIDINYLOXYPROPYLMALEIMIDE F 18; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INTEGRIN RECEPTOR; MELANOCORTIN 1 RECEPTOR; NEUROTENSIN RECEPTOR; NITROPHENYL FLUOROPROPANOATE F 18; PENTETREOTIDE; PEPTIDE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SUCCINIMIDYL FLUOROBENZOATE F 18; TRIENTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; YTTRIUM 86;

DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MENINGIOMA; NEUROENDOCRINE TUMOR; NEUROFIBROMA; NONHUMAN; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MOLECULAR PROBES; NANOPARTICLES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78649325858     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.09.004     Document Type: Review

References (196)

1. Weissleder R., Mahmood U. Molecular imaging. Radiology 2001, 219:316-333.
2. Thakur M., Lentle B.C. Report of a summit on molecular imaging. Radiology 2005, 236:753-755.
3. Cai W., Rao J., Gambhir S.S., Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther. 2006, 5:2624-2633.
4. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580.
5. Hartwell L., Mankoff D., Paulovich A., Ramsey S., Swisher E. Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006, 24:905-908.
6. Aebersold R., Anderson L., Caprioli R., Druker B., Hartwell L., Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J. Proteome Res. 2005, 4:1104-1109.
7. Beyer T., Townsend D.W., Brun T., Kinahan P.E., Charron M., Roddy R., Jerin J., Young J., Byars L., Nutt R. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 2000, 41:1369-1379.
8. Catana C., Wu Y., Judenhofer M.S., Qi J., Pichler B.J., Cherry S.R. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J. Nucl. Med. 2006, 47:1968-1976.
9. Even-Sapir E., Lerman H., Lievshitz G., Khafif A., Fliss D.M., Schwartz A., Gur E., Skornick Y., Schneebaum S. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J. Nucl. Med. 2003, 44:1413-1420.
10. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2002, 2:683-693.
11. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2002, 2:11-18.
12. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
13. Lee S., Xie J., Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem. Rev. 2010, 110:3087-3111.
14. Chen K., Chen X. Design and development of molecular imaging probes. Curr. Top. Med. Chem. 2010, 10:1227-1236.
15. Anderson C.J., Bulte J.W., Chen K., Chen X., Khaw B.A., Shokeen M., Wooley K.L., VanBrocklin H.F. Design of targeted cardiovascular molecular imaging probes. J. Nucl. Med. 2010, 51(Suppl 1):3S-17S.
16. Rudin M., Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:123-131.
17. Anderson C.J., Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm. 2009, 24:379-393.
18. Louie A. Multimodality imaging probes: design and challenges. Chem. Rev. 2010, 110:3146-3195.
19. Lee S., Xie J., Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010, 49:1364-1376.
20. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 2004, 24:357-397.
21. Hong H., Zhang Y., Sun J., Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 2010, 39:11-27.
22. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed Engl. 2008, 47:8998-9033.
23. Kayani I., Groves A.M. 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin. Med. 2006, 6:240-244.
24. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., Cheson B.D., O'Shaughnessy J., Guyton K.Z., Mankoff D.A., Shankar L., Larson S.M., Sigman C.C., Schilsky R.L., Sullivan D.C. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 2005, 11:2785-2808.
25. Rohren E.M., Turkington T.G., Coleman R.E. Clinical applications of PET in oncology. Radiology 2004, 231:305-332.
26. Boerman O.C., Oyen W.J., Corstens F.H. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 2000, 30:195-208.
27. Weiner R.E., Thakur M.L. Radiolabeled peptides in diagnosis and therapy. Semin. Nucl. Med. 2001, 31:296-311.
28. Blok D., Feitsma R.I., Vermeij P., Pauwels E.J. Peptide radiopharmaceuticals in nuclear medicine. Eur. J. Nucl. Med. 1999, 26:1511-1519.
29. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev. Med. Chem. 2006, 6:227-234.
30. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61:1781-1785.
31. Liu S., Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug. Chem. 2001, 12:7-34.
32. Deutscher S.L. Phage display in molecular imaging and diagnosis of cancer. Chem. Rev. 2010, 110:3196-3211.
33. Petrenko V. Evolution of phage display: from bioactive peptides to bioselective nanomaterials. Expert Opin. Drug Deliv. 2008, 5:825-836.
34. Ueberberg S., Schneider S. Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo. Regul. Pept. 2010, 160:1-8.
35. Brown K.C. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr. Pharm. Des. 2010, 16:1040-1054.
36. Newton J., Deutscher S.L. Phage peptide display. Handb. Exp. Pharmacol. 2008, 145-163.
37. Sun X., Niu G., Yan Y., Yang M., Chen K., Ma Y., Chan N., Shen B., Chen X. Phage display-derived peptides for osteosarcoma imaging. Clin. Cancer Res. 2010, 16:4268-4277.
38. Q. Cao, S. Liu, G. Niu, K. Chen, Y. Yan, Z. Liu, X. Chen, Phage display peptide probes for imaging early response to bevacizumab treatment, Amino Acids (in press).
39. Mading P., Fuchtner F., Wust F. Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl. Radiat. Isot. 2005, 63:329-332.
40. Vaidyanathan G., Zalutsky M.R. Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat. Protoc. 2006, 1:1655-1661.
41. Chen X., Park R., Hou Y., Khankaldyyan V., Gonzales-Gomez I., Tohme M., Bading J.R., Laug W.E., Conti P.S. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1081-1089.
42. Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., Bading J.R., Moats R., Laug W.E., Conti P.S. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 2004, 31:179-189.
43. Wuest F., Berndt M., Bergmann R., van den Hoff J., Pietzsch J. Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins. Bioconjug. Chem. 2008, 19:1202-1210.
44. Kolb H.C., Finn M.G., Sharpless K.B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed Engl. 2001, 40:2004-2021.
45. Kolb H.C., Sharpless K.B. The growing impact of click chemistry on drug discovery. Drug Discov. Today 2003, 8:1128-1137.
46. Hausner S.H., Marik J., Gagnon M.K., Sutcliffe J.L. In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides. J. Med. Chem. 2008, 51:5901-5904.
47. Li Z.B., Wu Z., Chen K., Chin F.T., Chen X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug. Chem. 2007, 18:1987-1994.
48. Kolb H.C., Chen K., Walsh J.C., Liang Q.W., Padgett H.C., Farhad K. Click Chemistry-derived Cyclopeptide Derivatives as Imaging Agents for Integrins 2008, WO 2008/033561.
49. Kolb H.C., Chen K., Walsh J.C., Gangadharmath U., Kasi D., Wang B., Duclos B., Liang Q.W., Padgett H.C., Farhad K. Click chemistry-derived cyclic peptidomimetics as integrin markers 2008, WO 2008/033557.
50. Kolb H.C., Chen K., Walsh J.C., Kasi D., Mocharla V.P., Chen G., Liang Q.W., Zhao T.M. Cyclic azapeptides as integrin markers 2009, WO 2009/018175.
51. Kolb H.C., Chen K., Walsh J.C., Liang Q.W. Cyclopeptides containing RGD mimetics as imaging markers for integrins 2009, WO 2009/134382.
52. Nwe K., Brechbiel M.W. Growing applications of "click chemistry" for bioconjugation in contemporary biomedical research. Cancer Biother. Radiopharm. 2009, 24:289-302.
53. Blackman M.L., Royzen M., Fox J.M. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J. Am. Chem. Soc. 2008, 130:13518-13519.
54. Devaraj N.K., Weissleder R., Hilderbrand S.A. Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjug. Chem. 2008, 19:2297-2299.
55. Rossin R., Verkerk P.R., van den Bosch S.M., Vulders R.C., Verel I., Lub J., Robillard M.S. In vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed Engl. 2010, 49:3375-3378.
56. Sun X., Anderson C.J. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol. 2004, 386:237-261.
57. Shokeen M., Anderson C.J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 2009, 42:832-841.
58. Sosabowski J.K., Mather S.J. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat. Protoc. 2006, 1:972-976.
59. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des. 2007, 13:3-16.
60. Liang X., Sadler P.J. Cyclam complexes and their applications in medicine. Chem. Soc. Rev. 2004, 33:246-266.
61. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., Anderson C.J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med. Chem. 2004, 47:1465-1474.
62. Voss S.D., Smith S.V., DiBartolo N., McIntosh L.J., Cyr E.M., Bonab A.A., Dearling J.L., Carter E.A., Fischman A.J., Treves S.T., Gillies S.D., Sargeson A.M., Huston J.S., Packard A.B. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc. Natl Acad. Sci. U. S.A. 2007, 104:17489-17493.
63. Cai H., Li Z., Huang C.W., Shahinian A.H., Wang H., Park R., Conti P.S. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved MicroPET imaging of integrin alpha(v)beta(3) expression. Bioconjug. Chem. 2010, 21:1417-1424.
64. Cai H., Li Z., Huang C.W., Park R., Shahinian A.H., Conti P.S. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3, 6, 10, 13, 16, 19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl. Med. Biol. 2010, 37:57-65.
65. Cai H., Fissekis J., Conti P.S. Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling. Dalton Trans. 2009, 5395-5400.
66. Chen Y.P., Chen F. Identifying targets for drug discovery using bioinformatics. Expert Opin. Ther. Targets 2008, 12:383-389.
67. Klee E.W., Finlay J.A., McDonald C., Attewell J.R., Hebrink D., Dyer R., Love B., Vasmatzis G., Li T.M., Beechem J.M., Klee G.G. Bioinformatics methods for prioritizing serum biomarker candidates. Clin. Chem. 2006, 52:2162-2164.
68. Rhodes D.R., Chinnaiyan A.M. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann. NY Acad. Sci. 2004, 1020:32-40.
69. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., Varambally S., Ghosh D., Chinnaiyan A.M. Oncomine 3.0: genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
70. Yang Y., Adelstein S.J., Kassis A.I. Target discovery from data mining approaches. Drug Discov. Today 2009, 14:147-154.
71. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
72. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2:91-100.
73. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
74. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
75. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
76. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem. 2006, 6:407-428.
77. Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90:561-565.
78. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 1999, 222:124-138.
79. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
80. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502.
81. Goh K.L., Yang J.T., Hynes R.O. Mesodermal defects and cranial neural crest apoptosis in alpha5 integrin-null embryos. Development 1997, 124:4309-4319.
82. Taverna D., Hynes R.O. Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res. 2001, 61:5255-5261.
83. Yang J.T., Rayburn H., Hynes R.O. Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 1993, 119:1093-1105.
84. Yang J.T., Rayburn H., Hynes R.O. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995, 121:549-560.
85. Huang C.W., Li Z., Cai H., Shahinian A.H., Conti P.S. microPET imaging of integrin alpha2beta1 expression using 64Cu-labeled DGEA peptides. J. Nucl. Med. 2010, 51(Suppl 2):193.
86. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291:50-54.
87. Haubner F.D., R., Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the ?v?3 integrin for a new cancer therapy. Angew. Chem. Int. Ed Engl. 1997, 36:1374-1389.
88. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., Stocklin G., Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 1999, 40:1061-1071.
89. Chen X., Park R., Shahinian A.H., Bading J.R., Conti P.S. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 2004, 31:11-19.
90. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40:539-551.
91. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. Eur. J. Nucl. Med. Mol. Imaging 2006, 33(Suppl 1):54-63.
92. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 2001, 42:326-336.
93. Haubner R., Kuhnast B., Mang C., Weber W.A., Kessler H., Wester H.J., Schwaiger M. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug. Chem. 2004, 15:61-69.
94. Haubner R., Weber W.A., Beer A.J., Vabuliene E., Reim D., Sarbia M., Becker K.F., Goebel M., Hein R., Wester H.J., Kessler H., Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005, 2:e70.
95. Beer A.J., Haubner R., Wolf I., Goebel M., Luderschmidt S., Niemeyer M., Grosu A.L., Martinez M.J., Wester H.J., Weber W.A., Schwaiger M. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J. Nucl. Med. 2006, 47:763-769.
96. Beer A.J., Haubner R., Goebel M., Luderschmidt S., Spilker M.E., Wester H.J., Weber W.A., Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med. 2005, 46:1333-1341.
97. Beer A.J., Haubner R., Sarbia M., Goebel M., Luderschmidt S., Grosu A.L., Schnell O., Niemeyer M., Kessler H., Wester H.J., Weber W.A., Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res. 2006, 12:3942-3949.
98. Beer A.J., Grosu A.L., Carlsen J., Kolk A., Sarbia M., Stangier I., Watzlowik P., Wester H.J., Haubner R., Schwaiger M. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2007, 13:6610-6616.
99. Beer A.J., Lorenzen S., Metz S., Herrmann K., Watzlowik P., Wester H.J., Peschel C., Lordick F., Schwaiger M. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J. Nucl. Med. 2008, 49:22-29.
100. Chen X., Hou Y., Tohme M., Park R., Khankaldyyan V., Gonzales-Gomez I., Bading J.R., Laug W.E., Conti P.S. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J. Nucl. Med. 2004, 45:1776-1783.
101. Boturyn D., Coll J.L., Garanger E., Favrot M.C., Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc. 2004, 126:5730-5739.
102. Chen X., Liu S., Hou Y., Tohme M., Park R., Bading J.R., Conti P.S. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 2004, 6:350-359.
103. Chen X., Park R., Tohme M., Shahinian A.H., Bading J.R., Conti P.S. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug. Chem. 2004, 15:41-49.
104. Chen X., Tohme M., Park R., Hou Y., Bading J.R., Conti P.S. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol. Imaging 2004, 3:96-104.
105. Dijkgraaf I., Liu S., Kruijtzer J.A., Soede A.C., Oyen W.J., Liskamp R.M., Corstens F.H., Boerman O.C. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl. Med. Biol. 2007, 34:29-35.
106. Wu Z., Li Z.B., Chen K., Cai W., He L., Chin F.T., Li F., Chen X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J. Nucl. Med. 2007, 48:1536-1544.
107. Zhang X., Xiong Z., Wu Y., Cai W., Tseng J.R., Gambhir S.S., Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J. Nucl. Med. 2006, 47:113-121.
108. Poethko T., Schottelius M., Thumshirn G., Hersel U., Herz M., Henriksen G., Kessler H., Schwaiger M., Wester H.J. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J. Nucl. Med. 2004, 45:892-902.
109. Dijkgraaf I., Kruijtzer J.A., Liu S., Soede A.C., Oyen W.J., Corstens F.H., Liskamp R.M., Boerman O.C. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:267-273.
110. Dijkgraaf I., Rijnders A.Y., Soede A., Dechesne A.C., van Esse G.W., Brouwer A.J., Corstens F.H., Boerman O.C., Rijkers D.T., Liskamp R.M. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1, 3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org. Biomol. Chem. 2007, 5:935-944.
111. Janssen M., Oyen W.J., Massuger L.F., Frielink C., Dijkgraaf I., Edwards D.S., Radjopadhye M., Corstens F.H., Boerman O.C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 2002, 17:641-646.
112. Li Z.B., Cai W., Cao Q., Chen K., Wu Z., He L., Chen X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med. 2007, 48:1162-1171.
113. Liu S., Hsieh W.Y., Jiang Y., Kim Y.S., Sreerama S.G., Chen X., Jia B., Wang F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug. Chem. 2007, 18:438-446.
114. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., Gambhir S.S., Chen X. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 2005, 46:1707-1718.
115. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol. Pharm. 2006, 3:472-487.
116. Cai H., Li Z., Huang C.W., Shahinian A.H., Wang H., Park R., Conti P.S. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved MicroPET imaging of integrin alphavbeta3 expression. Bioconjug. Chem. 2010, 21:1417-1424.
117. Morrison M.S., Ricketts S.A., Barnett J., Cuthbertson A., Tessier J., Wedge S.R. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J. Nucl. Med. 2009, 50:116-122.
118. Mittra E., Goris L., Iagaru A.H., Kardan A., Liu S., Shen B., Chin F.T., Chen X., Gambhir S.S. First in man studies of [18F]FPPRGD2: A novel PET radiopharmaceutical for imaging alphavbeta3 integrin levels. J. Nucl. Med. 2010, 51(Suppl 2):1433.
119. Weckbecker G., Lewis I., Albert R., Schmid H.A., Hoyer D., Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2003, 2:999-1017.
120. Bodei L., Paganelli G., Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J. Nucl. Med. 2006, 47:375-377.
121. Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann. Oncol. 1999, 10(Suppl 2):S17-S21.
122. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:781-793.
123. Scarpignato C., Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001, 47(Suppl 2):1-29.
124. Rufini V., Calcagni M.L., Baum R.P. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 2006, 36:228-247.
125. Anderson C.J., Dehdashti F., Cutler P.D., Schwarz S.W., Laforest R., Bass L.A., Lewis J.S., McCarthy D.W. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 2001, 42:213-221.
126. Koukouraki S., Strauss L.G., Georgoulias V., Schuhmacher J., Haberkorn U., Karkavitsas N., Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:460-466.
127. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., Kovacs P., Von Guggenberg E., Bale R., Virgolini I.J. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007, 48:508-518.
128. Win Z., Rahman L., Murrell J., Todd J., Al-Nahhas A. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:506.
129. Dimitrakopoulou-Strauss A., Georgoulias V., Eisenhut M., Herth F., Koukouraki S., Macke H.R., Haberkorn U., Strauss L.G. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:823-830.
130. Schottelius M., Wester H.J., Reubi J.C., Senekowitsch-Schmidtke R., Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug. Chem. 2002, 13:1021-1030.
131. Meisetschlager G., Poethko T., Stahl A., Wolf I., Scheidhauer K., Schottelius M., Herz M., Wester H.J., Schwaiger M. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J. Nucl. Med. 2006, 47:566-573.
132. Cescato R., Erchegyi J., Waser B., Piccand V., Maecke H.R., Rivier J.E., Reubi J.C. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J. Med. Chem. 2008, 51:4030-4037.
133. Waser B., Tamma M.L., Cescato R., Maecke H.R., Reubi J.C. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J. Nucl. Med. 2009, 50:936-941.
134. Wadas T.J., Eiblmaier M., Zheleznyak A., Sherman C.D., Ferdani R., Liang K., Achilefu S., Anderson C.J. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J. Nucl. Med. 2008, 49:1819-1827.
135. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003, 24:389-427.
136. Smith C.J., Volkert W.A., Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol. 2005, 32:733-740.
137. Rogers B.E., Bigott H.M., McCarthy D.W., Della Manna D., Kim J., Sharp T.L., Welch M.J. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug. Chem. 2003, 14:756-763.
138. Parry J.J., Kelly T.S., Andrews R., Rogers B.E. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug. Chem. 2007, 18:1110-1117.
139. Prasanphanich A.F., Nanda P.K., Rold T.L., Ma L., Lewis M.R., Garrison J.C., Hoffman T.J., Sieckman G.L., Figueroa S.D., Smith C.J. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl Acad. Sci. U. S.A. 2007, 104:12462-12467.
140. Garrison J.C., Rold T.L., Sieckman G.L., Figueroa S.D., Volkert W.A., Jurisson S.S., Hoffman T.J. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med. 2007, 48:1327-1337.
141. Chen X., Park R., Hou Y., Tohme M., Shahinian A.H., Bading J.R., Conti P.S. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 2004, 45:1390-1397.
142. Yang Y.S., Zhang X., Xiong Z., Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol. 2006, 33:371-380.
143. Dimitrakopoulou-Strauss A., Hohenberger P., Haberkorn U., Macke H.R., Eisenhut M., Strauss L.G. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J. Nucl. Med. 2007, 48:1245-1250.
144. Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., Maecke H.R. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1198-1208.
145. Zhang X., Cai W., Cao F., Schreibmann E., Wu Y., Wu J.C., Xing L., Chen X. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med. 2006, 47:492-501.
146. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., Reubi J.C. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J. Nucl. Med. 2008, 49:318-326.
147. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M.L., Waser B., Cescato R., Reubi J.C., Maecke H.R. Evaluation of a 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin. Cancer Res. 2009, 15:5240-5249.
148. Miao Y., Quinn T.P. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front. Biosci. 2007, 12:4514-4524.
149. Tatro J.B., Wen Z., Entwistle M.L., Atkins M.B., Smith T.J., Reichlin S., Murphy J.R. Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 1992, 52:2545-2548.
150. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., Eberle A.N. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989, 49:6352-6358.
151. Siegrist W., Stutz S., Eberle A.N. Homologous and heterologous regulation of alpha-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res. 1994, 54:2604-2610.
152. McQuade P., Miao Y., Yoo J., Quinn T.P., Welch M.J., Lewis J.S. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J. Med. Chem. 2005, 48:2985-2992.
153. Cheng Z., Chen J., Miao Y., Owen N.K., Quinn T.P., Jurisson S.S. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J. Med. Chem. 2002, 45:3048-3056.
154. Chen J., Cheng Z., Hoffman T.J., Jurisson S.S., Quinn T.P. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000, 60:5649-5658.
155. Cheng Z., Chen J., Quinn T.P., Jurisson S.S. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res. 2004, 64:1411-1418.
156. Chen J., Cheng Z., Owen N.K., Hoffman T.J., Miao Y., Jurisson S.S., Quinn T.P. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J. Nucl. Med. 2001, 42:1847-1855.
157. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl Acad. Sci. U. S.A. 1998, 95:12814-12818.
158. Cheng Z., Zhang L., Graves E., Xiong Z., Dandekar M., Chen X., Gambhir S.S. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J. Nucl. Med. 2007, 48:987-994.
159. Cheng Z., Xiong Z., Subbarayan M., Chen X., Gambhir S.S. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug. Chem. 2007, 18:765-772.
160. Froidevaux S., Calame-Christe M., Tanner H., Eberle A.N. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J. Nucl. Med. 2005, 46:887-895.
161. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., Eberle A.N. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J. Nucl. Med. 2002, 43:1699-1706.
162. Ren G., Liu Z., Miao Z., Liu H., Subbarayan M., Chin F.T., Zhang L., Gambhir S.S., Cheng Z. PET of malignant melanoma using 18F-labeled metallopeptides. J. Nucl. Med. 2009, 50:1865-1872.
163. K.T. Cheng, M.L. Thakur, HSDAVFTDNYTKLRKQ-NIe-AVKK-(3-OCH3, 4-OH)-FLNSSV-GABA-L-(Dap-(BMA)2)-64Cu, (2004).
164. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970, 169:1217-1218.
165. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., Moody T.W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 1996, 56:3486-3489.
166. Chakder S., Rattan S. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. J. Pharmacol. Exp. Ther. 1993, 266:392-399.
167. Virgolini I., Yang Q., Li S., Angelberger P., Neuhold N., Niederle B., Scheithauer W., Valent P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994, 54:690-700.
168. Blum A.M., Mathew R., Cook G.A., Metwali A., Felman R., Weinstock J.V. Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells. J. Neuroimmunol. 1992, 39:101-108.
169. Couvineau A., Laburthe M. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J. Clin. Endocrinol. Metab. 1985, 61:50-55.
170. Paul S., Said S.I. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J. Biol. Chem. 1987, 262:158-162.
171. Sreedharan S.P., Robichon A., Peterson K.E., Goetzl E.J. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl Acad. Sci. U. S.A. 1991, 88:4986-4990.
172. el Battari A., Martin J.M., Luis J., Pouzol O., Secchi J., Marvaldi J., Pichon J. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J. Biol. Chem. 1988, 263:17685-17689.
173. Svoboda M., De Neef P., Tastenoy M., Christophe J. Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2J. Eur. J. Biochem. 1988, 176:707-713.
174. Thakur M.L., Aruva M.R., Gariepy J., Acton P., Rattan S., Prasad S., Wickstrom E., Alavi A. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J. Nucl. Med. 2004, 45:1381-1389.
175. Zhang K., Aruva M.R., Shanthly N., Cardi C.A., Rattan S., Patel C., Kim C., McCue P.A., Wickstrom E., Thakur M.L. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J. Nucl. Med. 2008, 49:112-121.
176. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr. Rev. 1999, 20:876-913.
177. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
178. Korner M., Stockli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 2007, 48:736-743.
179. Brom M., Oyen W.J., Joosten L., Gotthardt M., Boerman O.C. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:1345-1355.
180. Wild D., Wicki A., Mansi R., Behe M., Keil B., Bernhardt P., Christofori G., Ell P.J., Macke H.R. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J. Nucl. Med. 2010, 51:1059-1067.
181. Vincent J.P. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell. Mol. Neurobiol. 1995, 15:501-512.
182. Reubi J.C., Waser B., Friess H., Buchler M., Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42:546-550.
183. Souaze F., Dupouy S., Viardot-Foucault V., Bruyneel E., Attoub S., Gespach C., Gompel A., Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006, 66:6243-6249.
184. Bergmann R., Scheunemann M., Heichert C., Mading P., Wittrisch H., Kretzschmar M., Rodig H., Tourwe D., Iterbeke K., Chavatte K., Zips D., Reubi J.C., Johannsen B. Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. Nucl. Med. Biol. 2002, 29:61-72.
185. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed Engl. 1998, 37:2754-2794.
186. Y. Yan, X. Chen, Peptide heterodimers for molecular imaging, Amino Acids, (in press).
187. Handl H.L., Vagner J., Han H., Mash E., Hruby V.J., Gillies R.J. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. Targets 2004, 8:565-586.
188. Li Z.B., Wu Z., Chen K., Ryu E.K., Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med. 2008, 49:453-461.
189. Liu Z., Li Z.B., Cao Q., Liu S., Wang F., Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J. Nucl. Med. 2009, 50:1168-1177.
190. Liu Z., Niu G., Wang F., Chen X. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1483-1494.
191. Welch M.J., Hawker C.J., Wooley K.L. The advantages of nanoparticles for PET. J. Nucl. Med. 2009, 50:1743-1746.
192. Cai W., Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007, 3:1840-1854.
193. Almutairi A., Rossin R., Shokeen M., Hagooly A., Ananth A., Capoccia B., Guillaudeu S., Abendschein D., Anderson C.J., Welch M.J., Frechet J.M. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl Acad. Sci. U. S.A. 2009, 106:685-690.
194. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2:47-52.
195. Lee H.Y., Li Z., Chen K., Hsu A.R., Xu C., Xie J., Sun S., Chen X. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 2008, 49:1371-1379.
196. Rodriguez-Porcel M., Cai W., Gheysens O., Willmann J.K., Chen K., Wang H., Chen I.Y., He L., Wu J.C., Li Z.B., Mohamedali K.A., Kim S., Rosenblum M.G., Chen X., Gambhir S.S. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J. Nucl. Med. 2008, 49:667-673.